Who should get access to experimental medicines prior to regulatory approval? And who should decide? A noted bioethicist and former biotech CEO at the center of the Josh Hardy compassionate use case speak out.
David Kroll, Contributor, Forbes
Wed, 08/27/2014 - 3:05pm
Who should get access to experimental medicines prior to regulatory approval? And who should decide? A noted bioethicist and former biotech CEO at the center of the Josh Hardy compassionate use case speak out.